Balchem [BCPC] vs Albemarle [ALB] Detailed Stock Comparison
Balchem
NASDAQ
Loading...
Albemarle
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Balchem wins in 13 metrics, Albemarle wins in 6 metrics, with 0 ties. Balchem appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Balchem | Albemarle | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 32.38 | 33.52 | Balchem |
| Price-to-Book Ratio | 3.61 | 1.26 | Albemarle |
| Debt-to-Equity Ratio | 16.38 | 35.76 | Balchem |
| PEG Ratio | 1.68 | 45.51 | Balchem |
| EV/EBITDA | 19.42 | 75.63 | Balchem |
| Profit Margin (TTM) | 14.48% | -22.39% | Balchem |
| Operating Margin (TTM) | 20.30% | 1.90% | Balchem |
| EBITDA Margin (TTM) | 20.30% | 1.90% | Balchem |
| Return on Equity | 11.99% | -9.99% | Balchem |
| Return on Assets (TTM) | 7.66% | -1.51% | Balchem |
| Free Cash Flow (TTM) | $146.34M | $-983.72M | Balchem |
| Dividend Yield | 0.54% | N/A | N/A |
| 1-Year Return | -18.53% | -13.59% | Albemarle |
| Price-to-Sales Ratio (TTM) | 4.65 | 1.93 | Albemarle |
| Enterprise Value | $4.72B | $14.49B | Albemarle |
| EV/Revenue Ratio | 4.79 | 2.85 | Albemarle |
| Gross Profit Margin (TTM) | 36.45% | 14.51% | Balchem |
| Revenue per Share (TTM) | $30 | $43 | Albemarle |
| Earnings per Share (Diluted) | $4.36 | $-11.12 | Balchem |
| Beta (Stock Volatility) | 0.92 | 1.63 | Balchem |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Balchem vs Albemarle Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Balchem | 3.09% | -4.07% | -11.47% | -13.68% | -12.11% | -11.53% |
| Albemarle | 0.70% | 0.14% | 10.12% | 31.26% | 32.66% | 3.51% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Balchem | -18.53% | 11.07% | 33.21% | 106.02% | 354.19% | 1,653.75% |
| Albemarle | -13.59% | -67.63% | -8.13% | 73.94% | 84.52% | 383.40% |
News Based Sentiment: Balchem vs Albemarle
Balchem
News based Sentiment: MIXED
Balchem experienced a mixed month, with positive Q2 earnings and an analyst upgrade countered by a 52-week low and bearish technical signals. This creates a complex investment picture, making October a significant month for the company's trajectory.
Albemarle
News sentiment data is not available for Albemarle at this time.
Performance & Financial Health Analysis: Balchem vs Albemarle
| Metric | BCPC | ALB |
|---|---|---|
| Market Information | ||
| Market Cap | $4.66B | $9.85B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 137,710 | 5,303,950 |
| 90 Day Avg. Volume | 154,037 | 4,228,367 |
| Last Close | $144.64 | $88.22 |
| 52 Week Range | $139.17 - $185.96 | $49.43 - $113.91 |
| % from 52W High | -22.22% | -22.55% |
| All-Time High | $186.03 (Jul 29, 2024) | $334.55 (Nov 07, 2022) |
| % from All-Time High | -22.25% | -73.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | -0.21% |
| Quarterly Earnings Growth | 0.19% | 15.89% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | -0.22% |
| Operating Margin (TTM) | 0.20% | 0.02% |
| Return on Equity (TTM) | 0.12% | -0.10% |
| Debt to Equity (MRQ) | 16.38 | 35.76 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $39.07 | $66.24 |
| Cash per Share (MRQ) | $2.02 | $12.91 |
| Operating Cash Flow (TTM) | $187.33M | $1.15B |
| Levered Free Cash Flow (TTM) | $126.15M | $-349,651,872 |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.54% | N/A |
| Last 12-Month Dividend | $0.87 | N/A |
Valuation & Enterprise Metrics Analysis: Balchem vs Albemarle
| Metric | BCPC | ALB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 32.38 | 33.52 |
| Forward P/E | 28.93 | 45.51 |
| PEG Ratio | 1.68 | 45.51 |
| Price to Sales (TTM) | 4.65 | 1.93 |
| Price to Book (MRQ) | 3.61 | 1.26 |
| Market Capitalization | ||
| Market Capitalization | $4.66B | $9.85B |
| Enterprise Value | $4.72B | $14.49B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.79 | 2.85 |
| Enterprise to EBITDA | 19.42 | 75.63 |
| Risk & Other Metrics | ||
| Beta | 0.92 | 1.63 |
| Book Value per Share (MRQ) | $39.07 | $66.24 |
Financial Statements Comparison: Balchem vs Albemarle
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BCPC | ALB |
|---|---|---|
| Revenue/Sales | $255.47M | $1.08B |
| Cost of Goods Sold | $162.35M | $920.58M |
| Gross Profit | $93.11M | $156.30M |
| Research & Development | $4.30M | $14.10M |
| Operating Income (EBIT) | $51.44M | $18.70M |
| EBITDA | $63.18M | $190.70M |
| Pre-Tax Income | $49.01M | $-18.97M |
| Income Tax | $10.73M | $-3.98M |
| Net Income (Profit) | $38.28M | $49.30M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BCPC | ALB |
|---|---|---|
| Cash & Equivalents | $49.90M | $1.52B |
| Total Current Assets | $340.24M | $4.11B |
| Total Current Liabilities | $139.56M | $1.94B |
| Long-Term Debt | $204.14M | $3.23B |
| Total Shareholders Equity | $1.21B | $10.27B |
| Retained Earnings | $1.03B | $5.43B |
| Property, Plant & Equipment | $340.80M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BCPC | ALB |
|---|---|---|
| Operating Cash Flow | $38.04M | $564.30M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | $30.90M | $362.76M |
| Debt Repayment | $-29.05M | $-10.81M |
| Common Stock Repurchase | $-5.33M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BCPC | ALB |
|---|---|---|
| Shares Short | 425,613 | 14.73M |
| Short Ratio | 3.01 | 3.89 |
| Short % of Float | 0.02% | 0.19% |
| Average Daily Volume (10 Day) | 137,710 | 5,303,950 |
| Average Daily Volume (90 Day) | 154,037 | 4,228,367 |
| Shares Outstanding | 32.53M | 117.56M |
| Float Shares | 32.28M | 117.09M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.91% | 0.99% |
Dividend Analysis & Yield Comparison: Balchem vs Albemarle
| Metric | BCPC | ALB |
|---|---|---|
| Last 12-Month Dividend | $0.87 | N/A |
| Last 12-Month Dividend Yield | 0.54% | N/A |
| 3-Year Avg Annual Dividend | $0.79 | N/A |
| 3-Year Avg Dividend Yield | 0.55% | N/A |
| 3-Year Total Dividends | $2.37 | N/A |
| Ex-Dividend Date | Dec 26, 2024 | N/A |